Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953849 · ClinicalTrials.gov registry record · Phase 1
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
A Phase 1 study of Mouth Neoplasms, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00953849 is a Phase 1 study of Mouth Neoplasms that has completed, run by VA Office of Research and Development. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00953849, a Phase 1 study of Mouth Neoplasms, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The poor survival of Veterans with oral cancer underscores the significance of identifying new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic approach for oral cancer patients which lessen the immune inhibitory environment while maturing cells that can stimulate T cell reactivity against oral cancer cells.
Conditions Studied
Interventions
- DRUG Celecoxib
- DRUG Calcitriol
- DRUG Celecoxib plus Calcitriol
Study Locations (1)
South Carolina
- Ralph H. Johnson VA Medical Center, Charleston, SC - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953849
The ClinicalTrials.gov registry entry for NCT00953849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mouth Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Celecoxib is the first listed.
NCT00953849 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT00953849 about?
NCT00953849 is a clinical study titled "Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity". The poor survival of Veterans with oral cancer underscores the significance of identifying new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic approach for oral cancer patients which lessen the immune inhibitory environment while maturing cells that can stimula...
What is the current status of trial NCT00953849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2009-11. Estimated completion is 2015-12.
What conditions does trial NCT00953849 study?
This clinical trial studies the following conditions: Mouth Neoplasms.
What interventions are being tested in trial NCT00953849?
The interventions under investigation include: Celecoxib (DRUG), Calcitriol (DRUG), Celecoxib plus Calcitriol (DRUG).
Who is sponsoring clinical trial NCT00953849?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00953849 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mouth Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.